Related references
Note: Only part of the references are listed.Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Enriqueta Felip et al.
CLINICAL LUNG CANCER (2018)
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Carlo Genova et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
Ross A. Soo et al.
LUNG CANCER (2018)
Targeting tumour microenvironment by tyrosine kinase inhibitor
Hor-Yue Tan et al.
MOLECULAR CANCER (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Sven Wind et al.
CLINICAL PHARMACOKINETICS (2017)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
Shirish Gadgeel et al.
LUNG CANCER (2017)
EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
Amit Joshi et al.
ONCOTARGETS AND THERAPY (2017)
New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Vera Hirsh
ONCOTARGETS AND THERAPY (2017)
1263PAFATINIB (A) FOLLOWED BY A + PACLITAXEL (P) OR INVESTIGATOR'S CHOICE OF SINGLE-AGENT CHEMOTHERAPY (IC) IN PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG: SUBGROUP ANALYSIS OF LUX-LUNG 5 (LL5)
K. Park et al.
ANNALS OF ONCOLOGY (2017)
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
M. Schuler et al.
ANNALS OF ONCOLOGY (2016)
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study
Isabelle Monnet et al.
LUNG CANCER (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung
Glenwood D. Goss et al.
ONCOLOGIST (2016)
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
Yijun Xu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Impact of genomic heterogeneity associated with acquired anti-EGFR resistance in colorectal cancers
Guoli Chen et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400
Roy S. Herbst et al.
CLINICAL CANCER RESEARCH (2015)
Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara et al.
CLINICAL CANCER RESEARCH (2015)
Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non-Small-Cell Lung Cancer
Federico Cappuzzo et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
EGFR tyrosine kinase inhibitors in squamous cell lung cancer
Fred R. Hirsch et al.
LANCET ONCOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Jean-Charles Soria et al.
LANCET ONCOLOGY (2015)
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Jacques De Greve et al.
LUNG CANCER (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Afatinib for the treatment of advanced non-small-cell lung cancer
Carlo Genova et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non-Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis
June-Koo Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non-Small-Cell Lung Cancer: The Bar Is Dropping
Adrian G. Sacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)
Tomoya Kawaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes
Lee M. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Jean-Louis Pujol et al.
LUNG CANCER (2014)
How Sensitive Are Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Gene-Sensitive Mutations?
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino et al.
LANCET ONCOLOGY (2013)
A Genomics-Based Classification of Human Lung Tumors
Danila Seidel et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations
Natasha Rekhtman et al.
CLINICAL CANCER RESEARCH (2012)
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Tudor Ciuleanu et al.
LANCET ONCOLOGY (2012)
Retrospective study of erlotinib in patients with advanced squamous lung cancer
Jeng-Sen Tseng et al.
LUNG CANCER (2012)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Structure-based view of epidermal growth factor receptor regulation
Kathryn M. Ferguson
ANNUAL REVIEW OF BIOPHYSICS (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
D. Li et al.
ONCOGENE (2008)
Erlotinib: applications in therapy and current status of research
Rachel E Sanborn et al.
Expert Review of Clinical Pharmacology (2008)
Structure and dynamics of the epidermal growth factor receptor C-terminal phosphorylation domain
NY Lee et al.
PROTEIN SCIENCE (2006)
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21
Gary M. Clark et al.
CLINICAL LUNG CANCER (2006)
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial
A Polychronis et al.
LANCET ONCOLOGY (2005)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Epidermal growth factor receptor in non-small-cell lung carcinomas:: Correlation between gene copy number and protein expression and impact on prognosis
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis
AP Meert et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Share Paper
